Doximity Inc SEC Filings

Doximity, Inc. reported solid growth for the quarter ended December 31, 2025. Revenue rose to $185.1 million from $168.6 million, while net income declined to $61.6 million from $75.2 million as operating expenses, including stock-based compensation, increased.

For the first nine months, revenue reached $499.5 million and net income was $176.9 million, both higher than a year earlier. The company generated $216.9 million in operating cash flow, held $64.8 million in cash plus $670.3 million in marketable securities, and spent $342.9 million on share repurchases.

Doximity closed the $36.3 million Pathway Medical acquisition, adding AI-based medical technology and goodwill, and ended with 126 customers generating at least $500,000 of trailing 12‑month subscription revenue, accounting for about 84% of revenue. Net revenue retention was 112%, indicating continued expansion within existing customers.

Doximity, Inc. reported that it issued a press release with financial results for its fiscal quarter ended December 31, 2025, and furnished that release as an exhibit. The company also announced that Chief Financial Officer and principal accounting officer Anna Bryson is taking a temporary medical leave. Effective February 3, 2026, Chief Accounting Officer Siddharth Sitaram was appointed interim principal financial officer and interim principal accounting officer, continuing a leadership team with deep internal experience at the company.

Doximity, Inc. reported that it issued a press release with financial results for its fiscal quarter ended December 31, 2025, and furnished that release as an exhibit. The company also announced that Chief Financial Officer and principal accounting officer Anna Bryson is taking a temporary medical leave. Effective February 3, 2026, Chief Accounting Officer Siddharth Sitaram was appointed interim principal financial officer and interim principal accounting officer, continuing a leadership team with deep internal experience at the company.

FMR LLC and Abigail P. Johnson filed Amendment No. 5 to a Schedule 13G reporting their beneficial ownership of Doximity Inc. Class A common stock as of 12/31/2025. They report beneficial ownership of 2,164,071.69 Class A shares, representing 1.6% of the outstanding class.

FMR LLC reports sole voting power over 2,155,851.97 shares and sole dispositive power over 2,164,071.69 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, without the purpose or effect of changing or influencing control of Doximity.

FMR LLC and Abigail P. Johnson filed Amendment No. 5 to a Schedule 13G reporting their beneficial ownership of Doximity Inc. Class A common stock as of 12/31/2025. They report beneficial ownership of 2,164,071.69 Class A shares, representing 1.6% of the outstanding class.

FMR LLC reports sole voting power over 2,155,851.97 shares and sole dispositive power over 2,164,071.69 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, without the purpose or effect of changing or influencing control of Doximity.

Doximity director Kira Scherer Wampler reported a routine set of equity transactions involving stock options and share sales. On February 2, 2026, she exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, which were convertible into Class A shares.

Those 2,000 Class B shares were converted into 2,000 Class A Common Stock and then sold the same day at a price of $37.33 per share under a pre-established Rule 10b5-1 trading plan. After these transactions, Wampler directly held 19,839 shares of Class A Common Stock and 458,700 derivative securities in the form of options tied to Class B Common Stock.

Doximity insider Kira Wampler has filed a notice to sell company stock. The filing reports a planned sale of 2,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $74,660 and 137,373,858 shares outstanding.

The 2,000 shares were acquired on February 2, 2026 via a stock option exercise paid in cash on the same date. Over the past three months, Wampler has already sold three separate 2,000-share blocks of Doximity common stock, with gross proceeds of $101,420, $132,880, and $89,300.

Doximity, Inc. director Form 4 shows option exercise, share conversion, and a small sale under a preset plan. On 01/02/2026, the reporting person exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, receiving an equivalent 2,000 Class B shares that are convertible into Class A shares.

That same day, 2,000 shares of Class B Common Stock converted into 2,000 shares of Class A Common Stock, and 2,000 Class A shares were sold at a price of $44.65 per share. After these transactions, the director beneficially owned 19,839 shares of Class A Common Stock directly and held 460,700 derivative securities in the form of stock options. The filing notes that the sale was made automatically under a Rule 10b5-1 trading plan adopted on November 12, 2024, indicating the trades were pre-arranged.

A shareholder of Doximity has filed a notice under Rule 144 to sell 2,000 shares of Doximity common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $89,300. These shares were acquired on the same date via a stock option exercise paid in cash.

Over the prior three months, the same seller disposed of an additional 4,000 common shares in two transactions, generating gross proceeds of $101,420 and $132,880. The filing notes that Doximity had 137,373,858 common shares outstanding at the time referenced, providing context for the size of the planned sale.

Doximity, Inc. reported that it has entered into an Agreement of Settlement to resolve a securities litigation case pending in the U.S. District Court for the Northern District of California. The proposed settlement calls for an aggregate payment of $31 million, which will be fully funded by insurance proceeds rather than by the company directly. If approved by the court and all conditions are met, all claims against Doximity and the named directors and officers will be dismissed without any admission of liability, fault or wrongdoing. The settlement is still subject to stockholder notice, court approval, and other customary conditions, and the company notes that appeals, opt-outs by individual plaintiffs, or issues with insurance carriers could affect the final outcome.

Doximity, Inc. director Form 4 shows an option exercise, share conversion and a small stock sale. On 12/01/2025, the reporting director exercised a stock option to acquire 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, which then converted into 2,000 shares of Class A Common Stock. The director sold 2,000 Class A shares at a price of $50.71 per share under a pre-set Rule 10b5-1 trading plan adopted on November 12, 2024. After these transactions, the director directly owned 19,839 shares of Class A Common Stock and held derivative securities representing 462,700 shares of Class B Common Stock, which are convertible into Class A shares under specified conditions.

Doximity insider files notice to sell common stock under Rule 144. The filing reports a planned sale of 2,000 shares of Doximity common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $101,420.00. These 2,000 shares were acquired on 12/01/2025 via a stock option exercise paid in cash on the same date. Common shares outstanding are listed as 137,373,858.

The filer also discloses prior sales over the past three months: 2,000 common shares on 11/03/2025 for gross proceeds of $132,880.00, 2,000 shares on 10/01/2025 for $140,020.00, and 2,000 shares on 09/02/2025 for $133,140.00. The signer represents that they are not aware of undisclosed material adverse information about Doximity.